[ Wed, Mar 24th 2021 ]: WOPRAI
[ Wed, Mar 24th 2021 ]: WOPRAI
[ Wed, Mar 24th 2021 ]: WOPRAI
[ Wed, Mar 24th 2021 ]: WOPRAI
[ Wed, Mar 24th 2021 ]: WOPRAI
[ Wed, Mar 24th 2021 ]: WOPRAI
[ Wed, Mar 24th 2021 ]: WOPRAI
[ Wed, Mar 24th 2021 ]: WOPRAI
[ Wed, Mar 24th 2021 ]: WOPRAI
[ Wed, Mar 24th 2021 ]: WOPRAI
[ Wed, Mar 24th 2021 ]: WOPRAI
[ Wed, Mar 24th 2021 ]: WOPRAI
[ Wed, Mar 24th 2021 ]: WOPRAI
[ Wed, Mar 24th 2021 ]: WOPRAI
[ Wed, Mar 24th 2021 ]: WOPRAI
[ Wed, Mar 24th 2021 ]: WOPRAI
[ Tue, Mar 23rd 2021 ]: WOPRAI
[ Tue, Mar 23rd 2021 ]: WOPRAI
[ Tue, Mar 23rd 2021 ]: WOPRAI
[ Tue, Mar 23rd 2021 ]: WOPRAI
[ Tue, Mar 23rd 2021 ]: WOPRAI
[ Tue, Mar 23rd 2021 ]: WOPRAI
[ Tue, Mar 23rd 2021 ]: WOPRAI
[ Tue, Mar 23rd 2021 ]: WOPRAI
[ Tue, Mar 23rd 2021 ]: WOPRAI
[ Tue, Mar 23rd 2021 ]: WOPRAI
[ Tue, Mar 23rd 2021 ]: WOPRAI
[ Tue, Mar 23rd 2021 ]: WOPRAI
[ Tue, Mar 23rd 2021 ]: WOPRAI
[ Tue, Mar 23rd 2021 ]: WOPRAI
[ Tue, Mar 23rd 2021 ]: WOPRAI
[ Tue, Mar 23rd 2021 ]: WOPRAI
[ Mon, Mar 22nd 2021 ]: WOPRAI
[ Mon, Mar 22nd 2021 ]: WOPRAI
[ Mon, Mar 22nd 2021 ]: WOPRAI
[ Mon, Mar 22nd 2021 ]: WOPRAI
[ Mon, Mar 22nd 2021 ]: WOPRAI
[ Mon, Mar 22nd 2021 ]: WOPRAI
[ Mon, Mar 22nd 2021 ]: WOPRAI
[ Mon, Mar 22nd 2021 ]: WOPRAI
[ Mon, Mar 22nd 2021 ]: WOPRAI
[ Mon, Mar 22nd 2021 ]: WOPRAI
[ Mon, Mar 22nd 2021 ]: WOPRAI
[ Mon, Mar 22nd 2021 ]: WOPRAI
[ Mon, Mar 22nd 2021 ]: WOPRAI
[ Mon, Mar 22nd 2021 ]: WOPRAI
[ Mon, Mar 22nd 2021 ]: WOPRAI
[ Mon, Mar 22nd 2021 ]: WOPRAI
Matthew Harrison Maintained (AKRO) at Buy with Decreased Target to $63 on, Mar 23rd, 2021
- 🞛 This publication is a summary or evaluation of another publication
Matthew Harrison of Morgan Stanley, Maintained "Akero Therapeutics, Inc." (AKRO) at Buy with Decreased Target from $70 to $63 on, Mar 23rd, 2021.
Matthew has made no other calls on AKRO in the last 4 months.
There are 3 other peers that have a rating on AKRO. Out of the 3 peers that are also analyzing AKRO, 0 agree with Matthew's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Matthew
- Edward Nash of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $46 on, Thursday, March 18th, 2021
- Michael Morabito of "Chardan Capital" Maintained at Strong Buy with Increased Target to $81 on, Wednesday, March 17th, 2021
- Etzer Darout of "Guggenheim" Initiated at Strong Buy and Held Target at $54 on, Friday, February 26th, 2021